Benign Prostatic Hyperplasia

April 2014

Start date

April 2014

Trial status

Completed

Patients enrolled

5

Trial quota

5

Canterbury Urology Research Trust are currently recruiting subjects for a new BPH study. The Principal Investigator for this trial is Stephen Mark

This study is using a single intraprostatic injection to reduce LUTS in patients with BPH.

Inclusion Criteria

  • Men ≥ 50 years
  • Lower Urinary Tract Symptoms (LUTS) attributable to BPH for ≥ 6 months
  • Peak flow ≥ 5 and ≤ 15 mL/sec
  • PSA ≤ 10ng/mL   (Subjects with PSA ≥ 4 to ≤ 10ng/mL  eligible only if prostate biopsy within 1 year)

Exclusion Criteria

Some medications such as:

  • 5α-reductase inhibitor within 6 months of dosing with study medication

 

 

For more information about this trial, please feel free to contact us